BioNJ's Prestigious Speaker Roster for Its 12th Annual C-Suite Summit

News provided by

Oct 07, 2024, 10:00 ET

TRENTON, N.J., Oct. 7, 2024 /PRNewswire/ -- BioNJ is hosting its C-Suite Summit this Thursday, October 10, 2024, at the Bridgewater Marriott. In its twelfth year, the C-Suite Summit convenes executives from across the life sciences sector, representing a diverse array of companies — from early stage start-ups to established industry leaders, spanning both public and private sectors, as well as revenue-generating and pre-revenue enterprises. Together, they engage in insightful discussions on the critical issues shaping C-Suite decision-making as the industry strives to bring groundbreaking treatments to market.

In the face of unprecedented change, the biopharmaceutical industry stands at a pivotal juncture. With the next wave of innovation on the horizon, this Summit offers a unique opportunity to reflect on the current landscape of life sciences and explore how companies can successfully navigate this dynamic era of transformation.

"As shifts in policy and fluctuations in biopharma investment continue, the future of innovation in our industry continues to be closely scrutinized," said BioNJ President and CEO Debbie Hart. "The C-Suite Summit offers a vital platform for industry leaders to engage in open dialogue, exploring where the most promising opportunities exist and how to collectively navigate and shape the next frontier in life sciences and medical breakthroughs."

The speaker roster, featuring world-class leaders, includes:

Britt Byers, Sr. Vice President, Human Resources NA, Kyowa Kirin
Jan Campbell, Managing Partner, Pharmaceuticals & Biotechnology, Korn Ferry
Donna Conroy, Founder & CEO, SciMar ONE
Vikki Conway, Sr. Vice President & Head, Human Resources US, Teva Pharmaceuticals
Kiran Dattani, Customer Success, Transformation, Strategy & Architecture, Google Cloud Healthcare & Life Sciences, Google
Tom Evegan, Principal, Strategy & Management Consulting; National Consulting Leader Life Sciences, RSM
Hon. Jim Greenwood, Former Congressman & Former President & CEO, BIO
Hisham Hamadeh, Ph.D., Sr. Vice President & Global Head, Data Science & AI, Genmab
John Harlow, Chief Commercial Officer, Melinta Therapeutics
Debbie Hart, President & CEO, BioNJ
Paul Hunter, Vice President, Market Access & Commercial Operations, Halozyme
Garrett Ingram, President & CEO, Cipla Therapeutics
Christopher Jackson, Managing Member, The Law Office of Christopher S. Jackson
Haripriya Jain, MS, MBA, Executive Director, Global Value & Access Consulting, Evidera, part of Thermo Fisher Scientific
Rohan Jain, General Manager, Commercial, Nusano
Harriet Keane, Partner, McKinsey & Company
Sydney Klein, Chief Information Security Officer & Head, IT Core Services, Bristol Myers Squibb
Keith Koharski, Executive Director, Global Development IT, Regeneron
Emer Leahy, Ph.D., MBA, President & CEO, PsychoGenics & Chair, BioNJ
Lisa LeCointe-Cephas, J.D., Partner, Compliance & Investigations & Global Chair, Life Sciences Sector, DLA Piper
Will Lewis, J.D., MBA, Chair & CEO, Insmed
Husseini Manji, M.D., F.R.C.P.C., Professor, Oxford University; Co-Chair, UK Govt MH Mission; Former Global Head, Neuroscience, Janssen/Johnson & Johnson
Jake McDowell, Vice President & Head, Market Access, Pricing & Value, Partner Therapeutics
Clive Meanwell, M.D., Chairman & Partner, Population Health Partners
Aamir Mecklai, Managing Director, Healthcare Investment Banking, Bank of America
Heather Meade, J.D., Principal, EY
Christopher Mortko, Ph.D., MBA, Vice President, Business Development & Licensing, Merck
Gina Murdoch, MBA, President & CEO, Multiple Sclerosis Association of America
Brandon Parry, Sr. Partner, McKinsey & Company
Tarek Rabah, President & CEO, Otsuka Pharmaceuticals
Deiva Ramachandran, Ph.D., Partner, Generative AI-Automation Practice Leader, Healthcare, Life Sciences, State & Local Govt., IBM
Arda Ural, Ph.D., Partner & Americas Industry Market Leader for Life Sciences and Healthcare, EY
Monika Vnuk, M.D., Sr. Vice President, Global Partnering & Business Development, Sanofi
Scott White, MBA, Chief Operations Officer, NA Innovative Medicine, Johnson & Johnson

The action-packed agenda includes these topics:

The Next Wave of Innovation in Life Sciences
Harnessing Change to Deliver Impactful Innovation
Policy Uncertainties in an Election Year
Market Access & Reimbursement
Topics in Talent: Attraction, Retention & Diversity
Research & Development in Mental Health
Continued Evolutions in Go-to-Market Models Including Patient Services
Evolving Capital Markets & Implications for Innovation
The Digital & AI Era in the Biopharma Industry: How Can Companies Across Functions Transition from Hype Into Reality?

Click here for the full agenda.

"From access, regulation and policy to talent and AI, our experts will dive into what the industry should be doing ― and how we can work together ― to foster medical innovation and ensure Patient access," added Hart. "We hope all stakeholders will join us for this very important discussion."

Click here to register. Registration is $695 for BioNJ Members and $895 for future BioNJ Members. The C-Suite Summit is closed to media.

Contact
Randi Bromberg
Sr. Vice President, Communications and Marketing
O) 609-890-3185
C) 609-955-1067
[email protected]

SOURCE BioNJ